Perspective Therapeutics (NYSE:CATX) Stock Price Expected to Rise, B. Riley Analyst Says

Perspective Therapeutics (NYSE:CATX - Get Free Report) had its price objective increased by B. Riley from $9.00 to $12.00 in a report issued on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. B. Riley's target price indicates a potential upside of 199.25% from the stock's current price.

Several other equities analysts have also commented on CATX. Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday. Brookline Capital Management upgraded Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. Scotiabank began coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target for the company. Finally, Cantor Fitzgerald raised shares of Perspective Therapeutics to a "strong-buy" rating in a report on Tuesday, March 4th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Perspective Therapeutics currently has an average rating of "Buy" and an average target price of $12.56.

Perspective Therapeutics Stock Up 15.9%

NYSE:CATX traded up $0.55 during mid-day trading on Monday, reaching $4.01. The stock had a trading volume of 1,041,086 shares, compared to its average volume of 1,086,422. Perspective Therapeutics has a 1-year low of $1.60 and a 1-year high of $16.55. The stock's 50 day simple moving average is $2.64 and its two-hundred day simple moving average is $2.83.

Insider Activity

In other Perspective Therapeutics news, Director Robert F. Williamson III bought 22,192 shares of the firm's stock in a transaction dated Friday, March 28th. The stock was acquired at an average price of $2.27 per share, with a total value of $50,375.84. Following the completion of the transaction, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. This represents a 45.62% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Johan M. Spoor purchased 22,026 shares of the company's stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the transaction, the chief executive officer now directly owns 59,383 shares of the company's stock, valued at $133,017.92. This trade represents a 58.96% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 115,696 shares of company stock valued at $256,344 over the last three months. Insiders own 3.72% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. Series C raised its stake in shares of Perspective Therapeutics by 4.3% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company's stock worth $9,375,000 after purchasing an additional 120,991 shares in the last quarter. Octagon Capital Advisors LP increased its holdings in Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company's stock worth $7,352,000 after buying an additional 882,528 shares during the last quarter. Affinity Asset Advisors LLC raised its position in Perspective Therapeutics by 71.1% during the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company's stock valued at $4,738,000 after acquiring an additional 924,196 shares in the last quarter. Millennium Management LLC bought a new position in Perspective Therapeutics during the fourth quarter valued at approximately $4,132,000. Finally, Nuveen LLC acquired a new stake in Perspective Therapeutics in the first quarter valued at approximately $2,647,000. Institutional investors and hedge funds own 54.66% of the company's stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.